New 4‐Amino‐1,2,3‐Triazole Inhibitors of Indoleamine 2,3‐Dioxygenase Form a Long‐Lived Complex with the Enzyme and Display Exquisite Cellular Potency

Citations Over TimeTop 21% of 2017 papers

Abstract

Indoleamine-2,3 dioxygenase 1 (IDO1) has emerged as a central regulator of immune responses in both normal and disease biology. Due to its established role in promoting tumour immune escape, IDO1 has become an attractive target for cancer treatment. A novel series of highly cell potent IDO1 inhibitors based on a 4-amino-1,2,3-triazole core have been identified. Comprehensive kinetic, biochemical and structural studies demonstrate that compounds from this series have a noncompetitive kinetic mechanism of action with respect to the tryptophan substrate. In co-complex crystal structures, the compounds bind in the tryptophan pocket and make a direct ligand interaction with the haem iron of the porphyrin cofactor. It is proposed that these data can be rationalised by an ordered-binding mechanism, in which the inhibitor binds an apo form of the enzyme that is not competent to bind tryptophan. These inhibitors also form a very tight, long-lived complex with the enzyme, which partially explains their exquisite cellular potency. This novel series represents an attractive starting point for the future development of potent IDO1-targeted drugs.

Related Papers

• → Indoleamine 2,3-Dioxygenase Does It(2015)3 cited
• → Pharmacological Inhibition of the Immunomodulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO) Cooperatively Leverages Cytotoxic Chemotherapy(2005)
• → ATP promotes immunosuppressive MSCs inhibiting lymphocyte proliferation and expressing indoleamine dioxygenase(2017)
• Screening of the inhibitory activity of Korea local plant extracts against indoleamine 2,3-dioxygenase (IDO) = 한국 자생식물 추출물의 Indoleamine 2,3-dioxygenase (IDO) 저해활성(2011)
• 教15-2 妊娠免疫とIDO (Indoleamine 2, 3-dioxygenase)(アレルギー疾患の発症における免疫・神経・内分泌系のクロストーク,ミニシンポジウム,教育コース15(基礎・その他),第22回日本アレルギー学会春季臨床大会)(2010)